<DOC>
	<DOCNO>NCT00830427</DOCNO>
	<brief_summary>This study ( A7881006 ) first multiple dose study moderate asthmatic subject aim determine safety efficacy PF-00610355 subject take PF-00610355 daily basis 4 week subject maintain inhaled corticosteroid .</brief_summary>
	<brief_title>A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Bronchial Diseases</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<criteria>Subjects physician document history diagnosis persistent asthma least 6 month prior Screening Visit 1 . Trough FEV1 must 50100 % predict Screening Visit 1 . Subjects maintain stable dose ICS previous month prior screen . Subjects severe asthma exacerbation 2 month prior screen . Subjects meet criterion 'very poorly control ' accord NIH EPR 3 guideline . Subjects evidence history cardiovascular disease include angina , myocardial , infarction , clinically significant cardiac arrhythmia ( eg , atrial fibrillation , atrial flutter , supraventricular tachycardia , ventricular tachycardia ) , systemic hypertension ( SBP &gt; 160 mmHg DBP &gt; 100mmHg ) , pulmonary hypertension cerebrovascular disease ( include transient ischaemic attack ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>asthma bronchial disease</keyword>
</DOC>